Tested IV Hepabig in liver-transplant patients with hepatitis B
Part of Digestive system, Infections clinical trials.
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to under 65 when you sign consent
- You had a liver transplant for hepatitis B–related severe liver disease
- Your hepatitis B surface test (HBsAg) was positive before your transplant
- You’ve already received IV Hepabig more than 3 times using a 10,000 IU every 4 weeks schedule
- You cannot have had a severe allergic reaction (anaphylaxis) to Hepabig or its ingredients
- You must not have certain infections, pregnancy/breastfeeding, or major lab/health conditions that disqualify you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
This trial tests an investigational drug called IB-001 to see how well it works and how safe it is. It is for healthy volunteers and people with chronic hepatitis B. The goal is to find the best dose and understand side effects.
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.